The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 07, 2015

Filed:

Dec. 30, 2010
Applicants:

Antonin DE Fougerolles, Brookline, MA (US);

Andrew Sprague, Haverhill, MA (US);

Jens Harborth, Boston, MA (US);

Maria Gabriela Belvisi, Aigburth, GB;

Mark Andrew Birrell, Upminster, GB;

Elizabeth Louise Hardaker, London, GB;

Matthew Copeland Catley, London, GB;

Inventors:

Antonin de Fougerolles, Brookline, MA (US);

Andrew Sprague, Haverhill, MA (US);

Jens Harborth, Boston, MA (US);

Maria Gabriela Belvisi, Aigburth, GB;

Mark Andrew Birrell, Upminster, GB;

Elizabeth Louise Hardaker, London, GB;

Matthew Copeland Catley, London, GB;

Assignee:

Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); C12Y 207/1101 (2013.01); C12N 2310/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3515 (2013.01);
Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.


Find Patent Forward Citations

Loading…